

## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner  
US Department of Commerce  
United States Patent and Trademark  
Office, PCT  
2011 South Clark Place Room  
CP2/5C24  
Arlington, VA 22202  
ETATS-UNIS D'AMERIQUE  
in its capacity as elected Office

Date of mailing (day/month/year) 02 November 2000 (02.11.00)	
International application No. PCT/GB00/00845	Applicant's or agent's file reference P021043WO
International filing date (day/month/year) 08 March 2000 (08.03.00)	Priority date (day/month/year) 09 March 1999 (09.03.99)
Applicant GLEN, Alastair, Campbell, Agnew et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:06 October 2000 (06.10.00)☐ in a notice effecting later election filed with the International Bureau on:2. The election ☒ was☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Juan Cruz Telephone No.: (41-22) 338.83.38
---	---

# PATENT COOPERATION TREATY

# PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>P021043W0</b>	<b>FOR FURTHER ACTION</b>		see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.
International application No. <b>PCT/GB 00/ 00845</b>	International filing date (day/month/year) <b>08/03/2000</b>	(Earliest) Priority Date (day/month/year) <b>09/03/1999</b>	
Applicant  <b>LAXDALE LIMITED et al.</b>			

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 4 sheets.



It is also accompanied by a copy of each prior art document cited in this report.

**1. Basis of the report**

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.



the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :



contained in the international application in written form.



filed together with the international application in computer readable form.



furnished subsequently to this Authority in written form.



furnished subsequently to this Authority in computer readable form.



the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.



the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

**4. With regard to the title,**



the text is approved as submitted by the applicant.



the text has been established by this Authority to read as follows:

**5. With regard to the abstract,**



the text is approved as submitted by the applicant.



the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

- 6. The figure of the drawings to be published with the abstract is Figure No.**



as suggested by the applicant.



because the applicant failed to suggest a figure.



because this figure better characterizes the invention.

1



None of the figures.

CLAIMS

1. An assay for detecting type IV cytosolic phospholipase A<sub>2</sub> (cPLA<sub>2</sub>) or a protein immunologically homologous to type IV cPLA<sub>2</sub>, the assay comprising use of red blood cells.
2. An assay according to claim 1 for use in the diagnosis of a disease in which dysfunction of cell signalling systems involving highly unsaturated fatty acids is implicated.
3. An assay according to claim 1 for use in monitoring the effectiveness of medication administered to a patient suffering from a disease in which dysfunction of cell signalling systems involving highly unsaturated fatty acids is implicated
4. An assay according to claim 1 for use in drug development for a disease in which dysfunction of cell signalling systems involving highly unsaturated fatty acids is implicated
5. A method of diagnosis of a disease in which dysfunction of cell signalling systems involving highly unsaturated fatty acids is implicated, said method comprising the detection of type IV cytosolic phospholipase A<sub>2</sub> (cPLA<sub>2</sub>) protein or a protein immunologically homologous to type IV cPLA<sub>2</sub> in or on red blood cells.
6. A method of monitoring the effectiveness of medication administered to a patient suffering from a disease in which dysfunction of cell signalling systems involving highly unsaturated fatty acids is implicated, said method comprising the detection of type IV cytosolic phospholipase A<sub>2</sub> (cPLA<sub>2</sub>) protein or a protein immunologically homologous to type IV cPLA<sub>2</sub> in or on red blood cells.
7. A method of drug development for a disease in which dysfunction of cell signalling systems involving highly unsaturated fatty acids is implicated, said method comprising the detection of type IV cytosolic phospholipase A<sub>2</sub> (cPLA<sub>2</sub>) protein or a protein immunologically homologous to type IV cPLA<sub>2</sub> in or on red blood cells.

8. An assay or method according to any one of claims 1 to 7 wherein the red blood cells are isolated from the human body.
- 5 9. An assay or method according to any one of claims 1 to 7 wherein said assay or method comprises use of a whole blood sample without prior isolation of said red blood cells.
- 10 10. An assay or method according to any one of claims 2 to 9 wherein said disease is a disease or disease process in which type IV cPLA<sub>2</sub> activity or concentration is altered from normal levels.
- 15 11. An assay or method according to anyone of claims 2 to 9 wherein said disease is a disease or disease process in which type IV cPLA<sub>2</sub> activity or concentration is increased.
- 20 12. An assay or method according to any one of claims 2 to 11 wherein the disease is schizophrenia, dyslexia, bipolar or manic depressive illness, cachexia or brain injury.
- 25 13. An assay or method according to claim 12 wherein the brain injury is stroke or mechanical brain injury.
- 30 14. An assay or method according to any one of claims 1 to 13 wherein the type IV cPLA<sub>2</sub> protein or the protein immunologically homologous to type IV cPLA<sub>2</sub> has a molecular weight in the range 80 to 110 kDa or in the range 70 to 80 kDa or in the range 50 to 60 kDa.
15. An assay or method according to any one of claims 1 to 13 wherein the type IV cPLA<sub>2</sub> protein or the protein immunologically homologous to type IV cPLA<sub>2</sub> has a molecular weight in the range 90 to 105 kDa or in the range 70 to 80 kDa or in the range 50 to 60 kDa.

16. An assay or method according to any preceding claim comprising the steps of collecting a sample of blood from a subject and detecting the proteins *ex vivo*.
- 5 17. An assay or method according to claim 16 further comprising one or more of the steps of separating the red cells from the other blood components, disrupting the red cells, detecting the proteins either directly or following a protein separation technique.
- 10 18. An assay or method according to claim 17 wherein the red cells are disrupted by sonication, freezing, nitrogen cavitation or lysis.
19. An assay or method according to any preceding claim wherein said proteins are detected by immunoassay.
- 15 20. An assay or method according to any preceding claim wherein said proteins are detected using an antibody or antibodies that recognise an epitope or epitopes from amino acids 82 to 749 of type IV cPLA<sub>2</sub> protein from human monocyte (U937) cells.
- 20 21. An assay or method according to any preceding claim wherein said proteins are detected using an antibody or antibodies raised against an epitope or epitopes from amino acids 82 to 749 of type IV cPLA<sub>2</sub> protein from human monocyte (U937 cells) or raised against an epitope or epitopes of a synthetic peptide matching amino acids 82 to 749 of type IV cPLA<sub>2</sub> protein from human monocyte (U937) cells.
- 25 22. An assay or method according to claim 20 or 21 wherein said epitope or epitopes are from a peptide sequence or sequences which comprise the catalytic centre of type IV cPLA<sub>2</sub> protein from human monocyte (U937) cells.
- 30 23. An assay or method according to claim 20 or 21 wherein said epitope or epitopes are from the peptide sequence of amino acids 241 to 260 of type IV cPLA<sub>2</sub> protein from human monocyte (U937) cells.

24. An assay or method according to claim 19 wherein said proteins are detected using an antibody or antibodies raised against an epitope or epitopes from amino acids 1 to 216 of type IV cPLA<sub>2</sub> protein from human monocyte (U937) cells.
- 5 25. An assay or method according to claims 20, 21, 22, 23 or 24 wherein two or more of the antibodies are used in combination or in sequence to detect the said proteins with the required specificity.
- 10 26. An assay or method according to any of claims 1 to 18 for detecting type IV cPLA<sub>2</sub> wherein said proteins are detected by substrate assay.
- 15 27. A protein obtainable by isolation from red blood cells, said protein being immunologically homologous to type IV cPLA<sub>2</sub> and having a molecular weight in the range 80 to 110 kDa or a molecular weight in the range 70 to 80 kDa or a molecular weight in the range 50 to 60 kDa.
- 20 28. A protein according to claim 27, said protein being immunologically homologous to type IV cPLA<sub>2</sub> and having a molecular weight in the range 90 to 105 kDa or a molecular weight in the range 70 to 80 kDa or a molecular weight in the range 50 to 60 kDa.
- 25 29. A diagnostic kit comprising means for disrupting red blood cells and further comprising an antibody or antibodies to a protein obtainable by isolation from red blood cells, said protein being type IV cPLA<sub>2</sub> protein or a protein immunologically homologous to type IV cPLA<sub>2</sub>.
- 30 30. A diagnostic kit according to claim 28 wherein said antibody or antibodies is/are raised against an epitope or epitopes from amino acids 82 to 749 of type IV cPLA<sub>2</sub> protein from human monocyte (U937) cells.
31. A diagnostic kit according to claim 28 wherein said antibody or antibodies is/are raised against an epitope or epitopes from a peptide sequence or sequences which

comprise the catalytic active centre of type IV cPLA<sub>2</sub> protein from human monocyte (U937) cells.

32. A diagnostic kit according to claim 28, 29 or 30 wherein said means for disrupting  
5 red blood cells is a means for lysing red blood cells.
33. A diagnostic kit according to claim 28, 29 or 30 which is suitable for near-patient testing.

## TENT COOPERATION TRE

## PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference <b>P021043WO</b>	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. <b>PCT/GB00/00845</b>	International filing date (day/month/year) <b>08/03/2000</b>	Priority date (day/month/year) <b>09/03/1999</b>
International Patent Classification (IPC) or national classification and IPC <b>G01N33/53</b>		
Applicant <b>LAXDALE LIMITED et al.</b>		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.



2. This REPORT consists of a total of 6 sheets, including this cover sheet.

- ☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 5 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand  <b>06/10/2000</b>	Date of completion of this report  <b>23.04.2001</b>
Name and mailing address of the international preliminary examining authority:   <b>European Patent Office</b> <b>D-80298 Munich</b> <b>Tel. +49 89 2399 - 0 Tx: 523656 epmu d</b> <b>Fax: +49 89 2399 - 4465</b>	Authorized officer  <b>Hinchliffe, P</b>  <b>Telephone No. +49 89 2399 8431</b> 



# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB00/00845

## I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

### Description, pages:

1-19 as originally filed

### Claims, No.:

1-33 as received on 04/04/2001 with letter of 04/04/2001

### Drawings, sheets:

1/4-4/4 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB00/00845

☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

### III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application.

☒ claims Nos. 5,6,8-26 with respect to I.A..

because:

☒ the said international application, or the said claims Nos. 5,6,8-26 relate to the following subject matter which does not require an international preliminary examination (*specify*):  
**see separate sheet**

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☐ no international search report has been established for the said claims Nos. .

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

### V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims 1-26,29-33

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB00/00845

	No:	Claims	27,28
Inventive step (IS)	Yes:	Claims	1-26,29-33
	No:	Claims	27,28
Industrial applicability (IA)	Yes:	Claims	1-4,7,27-33
	No:	Claims	

2. Citations and explanations  
**see separate sheet**

**ITEM III & V**

1. The subject matter of claims 1-26 involve using red blood cells (RBCs) in an assay to detect levels of cPLA<sub>2</sub>. Although the enzyme is known (see D2 as cited in the ISR) this is the first time it has been shown to be associated with RBCs. Consequently the subject matter of these claims fulfills the requirement of Article 33(2) PCT. The closest prior art document is regarded as D1 (as cited in the ISR). This document refers to the detection of a different phospholipase on RBCs and it is alleged that the assay of D1 would inactivate the cPLA<sub>2</sub> of the current application. Consequently it would appear to be inventive to look for the cPLA<sub>2</sub> on RBCs and consequently the requirement of Article 33(3) PCT is fulfilled for these claims.
2. Claims 27 and 28 are not novel contrary to the requirement of Article 33(2) PCT. Documents D1-D8 (as cited in the ISR) all disclose proteins which fall in to the broad definition found in the said claims:  
D1- protein derived from red blood cells (RBC) stated to be a cPLA (see abstract),  
D2- proteins of 85.2 and 110 kD with cPLA<sub>2</sub> activity (see abstract and col.2, line 36),  
D3-purified cPLA<sub>2</sub> of 110 kD (see figure 4, table B),  
D4-purified PLA<sub>2</sub> proteins of 60 and 110 kD (see p.4, l.34-42),  
D5-purified PLA<sub>2</sub> proteins of 60 and 110 kD (see p.4, l.26-33),  
D6-purified PLA<sub>2</sub> proteins of 60 and 110 kD (see p.4, l.26-33),  
D7-two cPLAs disclosed, one of 85 kD and the other of 30 kD (see col.2, l.26-27 and l. 48),  
D8-paralogs of cPLA<sub>2</sub>, however this document is not comprised within the state of the art as the priority document of the present application has been checked and found to be valid.

**Information concerning sufficiency of disclosure (Art. 5 PCT):** A newly discovered member of a particular protein family should be identified by its amino acid sequence. Immunological identity appears not to be specific enough when a number of proteins share the same function as evidenced by the large number of documents concerning PLAs cited in the search report. Specific antibodies should also be identified by deposit receipts in certain contracting states (EPO).

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/GB00/00845

3. Claims 29-33 refer to kits comprising means for disrupting RBCs and antibodies directed against cPLA<sub>2</sub> or immunologically homologous proteins. D4 and D5 both refer to immunoassay of the cPLA<sub>2</sub> (see D3 discussion and D4, col.22, l. 47). It is however considered that the skilled person would not take the components used in the immunoassays of these two documents and formulate them into kits involving a RBC disruption reagent as without the inventive knowledge there would be no need to make such a kit. These claims therefore involve an inventive step thus fulfilling the requirements of Article 33(3) PCT.
4. Claims 5,6,8-26, relate, either directly or by implication, to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

CHARTERED PATENT ATTORNEYS EUROPEAN PATENT ATTORNEYS TRADE MARK ATTORNEYS

TELEPHONE  
FACSIMILE  
  
WEBSITE  
E-MAIL

020-7242 8692  
020-7405 4166  
020-7831 8501  
www.carpmaels.com  
email@carpmaels.com

43 BLOOMSBURY SQUARE  
LONDON WC1A 2RA

AND AT MUNICH

IAN B P de M DEVAUX\*  
JOHN W M CARPMAEL\*†  
ALAN J JONES\*  
STEPHEN J COLGAN\*  
N KEITH HOWICK\*†  
ADRIAN J FISHER\*†  
CHRIS P MERCER\*†  
HUW G HALLYBONE\*†  
RICHARD E JACKSON\*†  
PAUL N HOWARD\*†  
ANNE WONG †  
ANTHONY C W P JAMES\*

MICHAEL J DONNAN\*  
PETER M JOHNSTON\*  
R DUDLEY HAWKINS\*  
B PATRICIA B HARRIS†  
SUSAN M THOMAS\*  
JANDAN M ALISS†  
BRUCE R COCKERTON\*  
CAMERON J MARSHALL\*  
HUGH R GOODFELLOW\*  
JASON N RICE\*  
SUSAN E KIRSCH\*  
ROBERT M C CARPMAEL\*

JOHN A MURPHY (MANAGER)

CONSULTANTS

DEREK G R GRUNDY S DAVID VOTIER OBE

\* Patent Attorney † Trade Mark Attorney

European Patent Office  
Erhardtstrasse 27  
D-80298 Munich  
GERMANY

\_ YOUR REF

OUR REF P021043WO: PNH/BRC/mmc

4th April 2001

Dear Sirs,

**Re: International Patent Application No. PCT/GB00/00845  
LAXDALE LIMITED**

I refer to your Communication dated 4th December 2000 on this International Application in which a period of three months, kindly extended to four months, was awarded for reply.

In consideration of the Examiner's objections the Applicant proposes to amend claim 1 to recite:

*Use of red blood cells in an assay for the purpose of detecting type IV cytosolic phospholipase A<sub>2</sub> (cPLA<sub>2</sub>) or a protein immunologically homologous to type IV cPLA<sub>2</sub>.*

Dependent claims 2 to 4 and 8 to 26 have been amended accordingly to reflect the new "use" format of claim 1.

Document D1 is concerned with the activity of an unspecified phospholipase A<sub>2</sub> (PLA<sub>2</sub>) enzyme and its detection in erythrocytes and blood plasma to predict the course of psoriasis. The Applicant has obtained a full copy of D1 and an English language translation thereof. I enclose copies thereof for the Examiner's perusal.

Inspection of D1 reveals that the assay disclosed therein is concerned only with PLA<sub>2</sub> activity generally. There is no reference to cytosolic PLA<sub>2</sub> enzymes (cPLA<sub>2</sub>) and

## FACSIMILE MESSAGE

To: EPO Munich  
Fax No.: 00 49 89 2399 4465

This fax comprises 7 sheets. If a sheet is missing, or imperfectly received, please contact us immediately (Tel: 020-7242 8692; Fax: 020-7405 4166). If you are not the addressee, please contact us immediately and then destroy this fax.

certainly no reference to the specific cytosolic PLA<sub>2</sub> enzyme, namely the type IV cytosolic PLA<sub>2</sub> enzyme, with which the present Application is concerned. There is therefore no disclosure or suggestion in D1 that red blood cells may be used to detect the type IV cytosolic PLA<sub>2</sub> enzyme. It is therefore submitted that the claims of the present Application define subject-matter which is both novel and inventive over D1.

As noted in the preceding paragraph, D1 makes no mention specifically of type IV cytosolic PLA<sub>2</sub> and for this reason alone, the Applicant believes that D1 cannot prejudice the patentability of the present Application. However, the Applicant can provide further evidence that the assay used by the authors of D1 would not even have been "suitable for" detecting type IV cytosolic PLA<sub>2</sub>, for the reasons set out below.


D1 detects PLA<sub>2</sub> in erythrocytes and blood plasma using the methodology of Tuzhilin and Saluen'ia which, as noted on page 2 of the translation of D1, involves a preliminary heat treatment of the sample at 60°C for 15 minutes to remove lipase activity. I enclose herewith, for the Examiner's information, a copy of the Russian language original and an English language translation of the methodology of Tuzhilin and Saluen'ia (Laboratornoe Delo, 6, 1795, pp334-5), which shows that the method is stated as being for the determination of PLA<sub>2</sub> activity generally, rather than cPLA<sub>2</sub> activity specifically. The Applicant is aware from a further paper (Mayer and Marshall, FASEB Journal, 7, 1993, pp339-348; copy enclosed herewith) that the 85-kDA type IV cPLA<sub>2</sub> enzyme denatures when held at 57°C for 5 minutes (see Table 2). It is therefore evident that the methodology used in D1, which involves a heating step at 60°C for 15 minutes, would not detect type IV cPLA<sub>2</sub>, which denatures when held at 57°C for 5 minutes. The assay of D1 would not therefore even be "suitable for" detecting type IV cPLA<sub>2</sub> and is not relevant to the patentability of the subject-matter of the present Application.

With regard to the other cited prior art, particularly D9 and D10, it is submitted that none of this prior art discloses or suggests that red blood cells may be used to detect type IV cytosolic PLA<sub>2</sub>. Claims 1 to 26 as amended of the present Application also therefore define patentable subject-matter over this prior art.

With regard to the objections against claims 27 and 28, the Applicant has disclaimed the type IV cPLA<sub>2</sub> enzyme disclosed in the prior art (see D2 for example). It is submitted that claims 27 and 28 are therefore novel over the prior art.

Reconsideration of this Application is respectfully requested. A replacement set of claims (replacement pages 20 to 24) are enclosed herewith in triplicate. A copy of the translations and articles referred to above are enclosed with the confirmation copy of this letter.

Yours truly,

  
HOWARD, PAUL NICHOLAS

Enc.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
14 September 2000 (14.09.2000)

PCT

(10) International Publication Number  
**WO 00/54052 A3**

(51) International Patent Classification<sup>7</sup>: G01N 33/573,  
33/80, C12N 9/20

(21) International Application Number: PCT/GB00/00845

(22) International Filing Date: 8 March 2000 (08.03.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
9905417.3 9 March 1999 (09.03.1999) GB  
9919952.3 23 August 1999 (23.08.1999) GB

(71) Applicant (for all designated States except US): LAX-  
DALE LIMITED [GB/GB]; Kings Park House, Laurelhill  
Business Park, Stirling FK7 9JQ (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GLEN, Alastair,

Campbell, Agnew [GB/GB]; 276 A Nithsdale Road,  
Glasgow G41 5LP (GB). MCDONALD, Donald, John  
[GB/GB]; 186 Cumbernauld Road, Glasgow G73 6HA  
(GB).


(74) Agents: HOWARD, Paul, Nicholas et al.; Carpmals &  
Ransford, 43 Bloomsbury Square, London WC1A 2RA  
(GB).

(81) Designated States (national): AE, AL, AM, AT, AU, AZ,  
BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK,  
DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID,  
IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,  
LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL,  
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ,  
UA, UG, US, UZ, VN, YU, ZA, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent  
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent

[Continued on next page]

(54) Title: DIAGNOSTIC TEST



(57) Abstract: An assay for detecting type IV cytosolic phospholipase A<sub>2</sub>(cPLA<sub>2</sub>) or a protein immunologically homologous to type IV cPLA<sub>2</sub>, the assay comprising use of red blood cells, particularly for use in the diagnosis of a disease in which dysfunction of cell signalling systems involving highly unsaturated fatty acids is implicated.



WO 00/54052 A3





(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(88) Date of publication of the international search report:  
21 December 2000

**Published:**

— With international search report.

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 00/00845

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 G01N33/573 G01N33/80 C12N9/20

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N C12Q C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE WPI Derwent Publications Ltd., London, GB; AN 1994-284640 XP002143989 FILIMONKOVA N.N.: "Predicting the course of psoriasis by determining the phospholipase A2 activity in the erythrocytes and blood plasma" &amp; RU 2 009 509 C (SVERD SKIN VENERAL DISEASES RES INST), 15 March 1994 (1994-03-15) the whole document</p> <p style="text-align: center;">--- -/--</p>	1-33

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

7 September 2000

Date of mailing of the international search report

20/09/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Pellegrini, P

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 90/00845

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CLARK J.D. ET AL.: "A novel arachidonic acid-selective cytosolic PLA2 contains a Ca2+ -dependent translocation domain with homology to PKC and GAP" CELL, vol. 65, 1991, pages 1043-1051, XP002143986 cited in the application	27,28
A	abstract	1-26, 29-33
X	--- ZHU X. ET AL.: "Quantitation of the cytosolic phospholipase A2 (type iv) in isolated human peripheral blood eosinophils by sandwich-ELISA" J. IMMUNOLOG. METH., vol. 199, 1996, pages 119-126, XP002143987	27,28
A	the whole document	1-26, 29-33
X	--- US 5 354 677 A (KNOPF JOHN L ET AL) 11 October 1994 (1994-10-11) claims	27,28
X	--- US 5 527 698 A (KNOPF JOHN L ET AL) 18 June 1996 (1996-06-18) claims	27,28
X	--- US 5 593 878 A (KNOPF JOHN L ET AL) 14 January 1997 (1997-01-14) claims	27,28
X	--- US 5 279 957 A (GROSS RICHARD) 18 January 1994 (1994-01-18) abstract claim 1	27,28
P,X	--- R. TODD PICKARD ET AL.: "Molecular cloning of two new human paralogs of 85-KDa cytosolic phospholipase A2" J. BIOL. CHEM., vol. 274, no. 13, 26 March 1999 (1999-03-26), pages 8823-8831, XP002143988 cited in the application	27,28
A	the whole document	1-26, 29-33
A	--- GATTAZ W.F. ET AL.: "Increased plasma phospholipase A2 activity in schizophrenic patients: reduction after neuroleptic therapy" BIOLOGICAL PSYCHIATRY, vol. 22, 1987, pages 421-426, XP000933408 the whole document	1-33
	---	

-/--

# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/GB90/00845

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>HUDSON C.J. ET AL.: "Phospholipases: in search of a genetic base of schizophrenia" PROSTAGLANDINS, LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, vol. 55, 1996, pages 119-122, XP000925733 the whole document</p> <p>-----</p>	1-33

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/00845


Patent document cited in search report		Publication date	Patent family member(s)	Publication date
RU 2009509	C	15-03-1994	NONE	
US 5354677	A	11-10-1994	US 5622832 A	22-04-1997
			US 5593878 A	14-01-1997
			US 5527698 A	18-06-1996
			US 5322776 A	21-06-1994
US 5527698	A	18-06-1996	US 5354677 A	11-10-1994
			US 5622832 A	22-04-1997
			US 5593878 A	14-01-1997
			US 5322776 A	21-06-1994
US 5593878	A	14-01-1997	US 5354677 A	11-10-1994
			US 5622832 A	22-04-1997
			US 5527698 A	18-06-1996
			US 5322776 A	21-06-1994
US 5279957	A	18-01-1994	NONE	

# PATENT COOPERATION TREATY

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

HOWARD, PAUL N.  
CARPMAELS & RANSFORD  
43 Bloomsbury Square  
London WC1A 2RA  
GRANDE BRETAGNE



## PCT

NOTIFICATION OF TRANSMITTAL OF  
THE INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT  
(PCT Rule 71.1)

Applicant's or agent's file reference <b>P021043WO</b>		<b>IMPORTANT NOTIFICATION</b>	
International application No. <b>PCT/GB00/00845</b>	International filing date (day/month/year) <b>08/03/2000</b>	Priority date (day/month/year) <b>09/03/1999</b>	
Applicant <b>LAXDALE LIMITED et al.</b>			

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

#### 4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer  Neumann, M  Tel. +49 89 2399-7351
--	---



# PATENT COOPERATION TREATY

DUE: 4-3-01

From the:  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

HOWARD, PAUL N.  
CARPMAELS & RANSFORD  
43 Bloomsbury Square  
London WC1A 2RA  
GRANDE BRETAGNE

RECEIVED  
- 6 DEC 2000  
CARPMAELS & RANSFORD  
ACTIONED .....

PCT

WRITTEN OPINION

(PCT Rule 66)

Date of mailing  
(day/month/year) 04.12.2000

Applicant's or agent's file reference

P021043WO

**REPLY DUE**

**within 3 month(s)**  
from the above date of mailing

International application No.

PCT/GB00/00845

International filing date (day/month/year)

08/03/2000

Priority date (day/month/year)

09/03/1999

International Patent Classification (IPC) or both national classification and IPC

G01N33/53

Applicant

LAXDALE LIMITED et al.

1. This written opinion is the first drawn up by this International Preliminary Examining Authority.

2. This opinion contains indications relating to the following items:

- I ☒ Basis of the opinion
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain document cited
- VII ☒ Certain defects in the international application
- VIII ☐ Certain observations on the international application

3. The applicant is hereby invited to reply to this opinion.

**When?** See the time limit indicated above. The applicant may, before the expiration of that time limit, request this Authority to grant an extension, see Rule 66.2(d).

**How?** By submitting a written reply, accompanied, where appropriate, by amendments, according to Rule 66.3. For the form and the language of the amendments, see Rules 66.8 and 66.9.

**Also:** For an additional opportunity to submit amendments, see Rule 66.4.  
For the examiner's obligation to consider amendments and/or arguments, see Rule 66.4 bis.  
For an informal communication with the examiner, see Rule 66.6.

If no reply is filed, the international preliminary examination report will be established on the basis of this opinion.

4. The final date by which the international preliminary examination report must be established according to Rule 69.2 is: 09/07/2001.

Name and mailing address of the international preliminary examining authority:



European Patent Office  
D-80298 Munich  
Tel. +49 89 2399 - 0 Tx: 523656 epmu d  
Fax: +49 89 2399 - 4465

Authorized officer / Examiner

Hinchliffe, P

Formalities officer (incl. extension of time limits)

Saavedra Martinez, V  
Telephone No. +49 89 2399 8621



## WRITTEN OPINION

International application No. PCT/GB00/00845

### I. Basis of the opinion

1. This opinion has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed".*):

#### Description, pages:

1-19 as originally filed

#### Claims, No.:

1-33 as originally filed

#### Drawings, sheets:

1/4-4/4 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item:

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:



## WRITTEN OPINION

International application No. PCT/GB00/00845

☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

### III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been and will not be examined in respect of:

- ☐ the entire international application,  
☒ claims Nos. 1-3,5,6,8-15,26 (with respect to I.A.),

because:

- ☒ the said international application, or the said claims Nos. 1-3,5,6,8-14,26 relate to the following subject matter which does not require an international preliminary examination (*specify*):  
**see separate sheet**
- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
- ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
- ☐ no international search report has been established for the said claims Nos. .

2. A written opinion cannot be drawn due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

- ☐ the written form has not been furnished or does not comply with the standard.  
☐ the computer readable form has not been furnished or does not comply with the standard.

### V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

#### 1. Statement

Novelty (N) Claims 1-11,12,14-18,26,27,28 (NO)

Inventive step (IS) Claims 19-25,29-33 (NO)

## WRITTEN OPINION

International application No. PCT/GB00/00845

---

Industrial applicability (IA)      Claims    1-3,5,6,8-15,26 (NO OPINION)

2. Citations and explanations  
**see separate sheet**

### **VII. Certain defects in the international application**

The following defects in the form or contents of the international application have been noted:  
**see separate sheet**

**ITEM V and VII**

1. Claims 1-11, 14-18, 26 are not novel contrary to the requirement of Article 33(2) PCT.  
D1 discloses an assay for predicting the course of psoriasis which involves assaying PLA<sub>2</sub> in a sample of human blood after haemolysis of RBC. Consequently this document teaches a method that involves RBC (as claimed) and furthermore relates to a disease that has a cell signalling system involving highly unsaturated fatty acids is implicated (psoriasis).
2. Claim 12 appears not to be novel contrary to Article 33(2) PCT. D9 and D10 both suggest that the detection of PLA<sub>2</sub> in serum samples of people may be diagnostic of mental illness, in particular Schizophrenia (see D9, introduction). Consequently the assay shown in D9 is novelty destroying for the subject matter of claim 12.
- 2.2 Claim 13 appears to be novel in the light of the documents cited in the ISR (Article 33(2) PCT), however there is no data to support the allegation that the levels of cPLA<sub>2</sub> may be altered by brain injury. Consequently this claim is contrary to the requirements of Article 5 PCT.
3. Claims 27 and 28 are not novel contrary to the requirement of Article 33(2) PCT. Documents D1-D8 (as cited in the ISR) all disclose proteins which fall in to the broad definition found in the said claims:  
D1- protein derived from red blood cells (RBC) stated to be a cPLA (see abstract),  
D2- proteins of 85.2 and 110 kD with cPLA<sub>2</sub> activity (see abstract and col.2, line 36),  
D3- purified cPLA<sub>2</sub> of 110 kD (see figure 4, table B),  
D4- purified PLA<sub>2</sub> proteins of 60 and 110 kD (see p.4, l.34-42),  
D5- purified PLA<sub>2</sub> proteins of 60 and 110 kD (see p.4, l.26-33),  
D6- purified PLA<sub>2</sub> proteins of 60 and 110 kD (see p.4, l.26-33),  
D7- two cPLAs disclosed, one of 85 kD and the other of 30 kD (see col.2, l.26-27 and l. 48),  
D8- paralogs of cPLA<sub>2</sub>, however this document is not comprised within the state of the art as the priority document of the present application has been checked and found to be valid.

4. Claims 19-25 refer to methods of assaying cPLA<sub>2</sub> whereby an immunoassay is performed. Both D3 and D4 relate to immunoassays used in the detection of cPLA<sub>2</sub> (see D3 discussion and D4, col.22, l. 47). However replacement of a substrate assay, as used in D1, by an immunoassay is obvious and does not involve an inventive step contrary to Article 33(3) PCT.
5. Claims 29-33 refer to kits comprising antibodies directed against cPLA<sub>2</sub>. D4 and D5 both refer to immunoassay of the cPLA<sub>2</sub> (see D3 discussion and D4, col.22, l. 47). It is considered that the skilled person could without inventive activity take the components used in the immunoassays of these two documents and formulate them into kits as claimed. These claims do not therefore involve an inventive step contrary to Article 33(3) PCT.
6. Claims 1-3,5,6,8-15,26, either directly or by implication from claim 16, relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).

**Information concerning sufficiency of disclosure (Art. 5 PCT):** A newly discovered member of a particular protein family should be identified by its amino acid sequence. Immunological identity appears not to be specific enough when a number of proteins share the same function as evidenced by the large number of documents concerning PLAs cited in the search report. Specific antibodies should also be identified by deposit receipts in certain contracting states (EPO).